Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEMICLOR vs EMBOLEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Prophylaxis of deep vein thrombosis (DVT) in surgical patients,Treatment of DVT,Treatment of pulmonary embolism,Prophylaxis of thromboembolic complications in medical patients
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
2-3 hours (terminal half-life in healthy adults); prolonged in hepatic impairment and elderly.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Primarily metabolized by desulfation and depolymerization in the liver; partial renal excretion.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Renal: ~50% (10% as unchanged drug, 40% as inactive metabolites); Biliary/fecal: ~50% (primarily as metabolites).
70–80% (primarily to albumin).
99% (primarily to albumin).
0.3–0.5 L/kg (indicates moderate tissue distribution).
0.1-0.2 L/kg (low, indicating limited extravascular distribution primarily in blood).
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
Oral: 60-75% (first-pass metabolism); Rectal: ~80%. IV: 100%.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
No specific dose adjustment for renal impairment; use caution in severe renal impairment (Cr Cl <30 m L/min) due to increased bleeding risk.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific adjustment for Child-Pugh class; use caution in severe hepatic impairment due to coagulopathy.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Not established; use only if benefit outweighs risk, with careful monitoring.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Increased risk of bleeding; consider lower doses and shorter infusion durations. No specific dosing guidelines; use clinical judgment.
No FDA black box warning is present for HEMICLOR.
Spinal or epidural hematomas may occur in patients receiving low molecular weight heparins and undergoing neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis.
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Risk of spinal/epidural hematoma with neuraxial interventions; increased risk of bleeding; heparin-induced thrombocytopenia (HIT); renal impairment; elderly; pregnancy.
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Hypersensitivity to heparin or pork products,Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Known bleeding disorder,Severe uncontrolled hypertension
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Avoid alcohol; may increase risk of GI bleeding. No significant food interactions beyond GI irritation; taking with food may slow absorption but does not affect efficacy.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second and third trimesters: May be used; risk of bleeding in mother/fetus. Avoid near delivery due to risk of maternal hemorrhage and epidural hematoma.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
Excretion into human milk is unknown; low molecular weight heparins are unlikely to be absorbed by infant. M/P ratio not available. Use with caution in breastfeeding women.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Pregnancy increases plasma volume and renal clearance; may require higher doses to achieve therapeutic anti-Xa levels. Monitor anti-Xa levels and adjust dose accordingly. No standard dose adjustment; individualize based on weight and anti-Xa monitoring.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
EMBOLEX (meloxicam) is an NSAID with preferential COX-2 inhibition; use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding, or history of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. Monitor renal function in elderly, dehydrated, or those on diuretics/ACE inhibitors. Not recommended for perioperative pain in CABG surgery.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, coffee-ground vomit) or cardiovascular symptoms (chest pain, shortness of breath) immediately.,Do not take with other NSAIDs (including over-the-counter ibuprofen or naproxen).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEMICLOR vs EMBOLEX, answered by our medical review team.
HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. EMBOLEX is a Low Molecular Weight Heparin that works by Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEMICLOR and EMBOLEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. The standard adult dose of EMBOLEX is: Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HEMICLOR and EMBOLEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . EMBOLEX is classified as Category C. Embolex (certoparin) is a low molecular weight heparin; no evidence of teratogenicity in animal studies. First trimester: Use only if clearly needed; no known fetal risk. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.